Scarica l'app Stockscreener
13.07
2.83%
-0.38
Dopo l'orario di chiusura:
13.20
0.13
+0.99%
Precedente Chiudi:
$13.45
Aprire:
$13.69
Volume 24 ore:
1.31M
Relative Volume:
0.31
Capitalizzazione di mercato:
$1.23B
Reddito:
-
Utile/perdita netta:
$-313.94M
Rapporto P/E:
-3.7279
EPS:
-3.506
Flusso di cassa netto:
$-284.57M
1 W Prestazione:
+5.74%
1M Prestazione:
-18.21%
6M Prestazione:
+55.41%
1 anno Prestazione:
+181.08%
Intervallo 1D:
$12.80
$13.83
Intervallo di 1 settimana:
$12.07
$13.83
Portata 52W:
$1.50
$16.33
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
13.07 | 1.16B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Downgrade | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Downgrade | Jefferies | Buy → Hold |
| 2026-04-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-04-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune launches melanoma therapy in US market By Investing.com - Investing.com Canada
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - Yahoo! Finance Canada
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
Replimune CEO and CFO sued for allegedly mislea... - Pluang
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - TradingView
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on October 5, 2026 - ACCESS Newswire
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities LawsuitContact Levi & Korsinsky - PR Newswire
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire
Preferred dividends of Replimune Group, Inc. – HAN:7R8 - TradingView
DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors - GlobeNewswire
REPL Investor Alert: Replimune Group, Inc. Securities Class Action NoticeContact Levi & Korsinsky - GlobeNewswire
Understanding the Setup: (REPL) and Scalable Risk - Stock Traders Daily
Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval - Stocktwits
Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before October 5, 2026 - ACCESS Newswire
REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Class Action Filed Against Replimune Group, Inc. (REPL) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Class action lawsuit filed against Replimune af... - Pluang
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
Securities Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
Replimune Group, Inc. (REPL) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Howard G. Smith joins probe into Replimune fraud after FDA BLA rejection - scanx.trade
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - ACCESS Newswire
Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug - Stocktwits
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission. - Pluang
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Replimune stock falls 3.79 percent as losses persist - AD HOC NEWS
Investors Urged to Contact Levi & Korsinsky For Information Before October 5, 2026Replimune Group, Inc. (REPL) - ACCESS Newswire
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 5, 2026 Deadline - ACCESS Newswire
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Replimune stock gains as share authorization doubles - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
REPL Shareholders Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) Shareholders of Class Action Lawsuit and October 5, 2026 Deadline - ACCESS Newswire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Replimune Group Inc (NASDAQ: REPL) Share Price, REPL Stock News, REPL Share Price & Updates - kalkine.com.au
Replimune Group, Inc. (REPL) Stock Analysis: A Potential 51.52% Upside In Biotech Innovations - DirectorsTalk Interviews
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026 - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Replimune shares plunge 84% after FDA rejects R... - Pluang
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors With Losses May Contact SueWallSt - PR Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - Morningstar
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of October 5, 2026 Deadline - ACCESS Newswire
REPL Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Replimune Group Inc Azioni (REPL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Chief Executive Officer |
Aug 10 '26 |
Sale |
12.97 |
39,341 |
510,253 |
708,151 |
| Hill Emily Luisa | Chief Financial Officer |
Aug 10 '26 |
Sale |
12.97 |
11,448 |
148,481 |
225,108 |
| Xynos Konstantinos | Chief Medical Officer |
Aug 10 '26 |
Sale |
12.97 |
11,447 |
148,468 |
224,215 |
| Schwendenman Andrew | Chief Accounting Officer |
Aug 10 '26 |
Sale |
12.97 |
7,632 |
98,987 |
99,425 |
| Sarchi Christopher | Chief Commercial Officer |
Jun 01 '26 |
Sale |
9.24 |
12,000 |
110,880 |
180,962 |
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):